Company Overview and News

 
Twinstar, Mavi Ind settle BSE dues

2018-04-10 thehindubusinessline
The BSE has withdrawn proceedings against Twinstar Industries and Mavi Industries for default in payment of annual listing fees (ALF) under the Code before the National Company Law Tribunal, Mumbai. The decision was on account of receiving full payment of outstanding annual listing fees from Twinstar Industries and Mavi Industries. Along with these two, the BSE had filed proceedings against seven listed companies that defaulted in payment of ALF under the Insolvency and Bankruptcy Code in December 2017.

 
BSE files bankruptcy case against 7 cos

2017-12-13 freepressjournal.in
Mumbai : BSE filed proceedings under the Insolvency and Bankruptcy Code (IBC) 2016 against seven listed companies for failing to pay the “Annual Listing Fees” (ALF) in spite of “advance intimation, reminders and grant of sufficient time in the past few years”.

 
BSE files bankruptcy case against 7 companies to recover dues

2017-12-13 moneycontrol
The BSE has become the first stock exchange in the country to drag seven firms listed on its platform to National Company Law Tribunal (NCLT) for failure to pay annual listing fees (ALF) even after granting them sufficient time and sending several reminders in the past few years.

 
BSE files insolvency case against seven companies

2017-12-12 livemint
Mumbai: In a first, a stock exchange is taking firms that have failed to pay up dues to the bankruptcy court. BSE Ltd on Tuesday said it is taking seven companies to National Company Law Tribunal (NCLT) under the Insolvency and Bankruptcy Code (IBC) for non-payment of annual listing fees.

 
Shares of Mavi Industries get delisted from NSE

2017-04-25 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...